Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

A titration package for reducing the severity of flu-like symptoms associated with treating a patient having multiple sclerosis with intramuscularly administered interferon-β-1a over an eight week period,

• wherein the titration package comprises interferon-β-1a and delivery devices for once a week intramuscular administration to a patient having multiple sclerosis according to a first schedule comprising:
• a first delivery device for intramuscular administration of 7.5 μg of interferon-β-1a to the patient in week one;
• a second delivery device for intramuscular administration of 15 μg of interferon-β-1a to the patient in week two;
• and
• a third delivery device for intramuscular administration of 22.5 μg of interferon-β-1a to the patient in week three;
• wherein the severity of the flu-like symptoms is reduced at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a throughout an eight week period which includes once a week intramuscular administration of 30 μg of interferon-β-1a to the patient in weeks four through eight when compared to the severity of flu-like symptoms at 4-6 hours and 12-15 hours after each administration of interferon-β-1a to the patient according to
• (i) a second schedule comprising once a week intramuscular administration of 30 μg of interferon-β-1a to a patient having multiple sclerosis for eight weeks and to
• (ii) a third schedule comprising:
• intramuscular administration of 7.5 μg of interferon-β-1a to the patient in weeks one and two;
• intramuscular administration of 15 μg of interferon-β-1a to the patient in weeks three and four;
• intramuscular administration of 22.5 μg of interferon-β-1a to the patient in weeks five and six;
• and
• intramuscular administration of 30 μg of interferon-β-1a to the patient in weeks seven and eight.